The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Anti‐rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen‐induced arthritis in rodents
Open accessAbstract
Background and purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease. Histone deacetylase inhibitors (HDACi), a new class of anti‐cancer agents, have recently been reported to exhibit potent anti‐inflammatory activities. A proof of concept study was carried out with suberoylanilide hydroxamic acid (SAHA) and MS‐275, two HDACi currently undergoing clinical investigations for various oncological indications. Experimental approach: The anti‐rheumatic effects of SAHA and MS‐275 were assessed in both mouse and rat collagen induced arthritis (CIA) models. Key results: SAHA exhibited moderate prophylactic efficacy. It attenuated paw swelling due to inflammation, decreased bone erosion in both mice and rats and reduced slightly the RA‐induced bone resorption in rats. However, SAHA could not inhibit the onset of arthritis. In contrast, MS‐275 displayed dramatic anti‐rheumatic activities. In prophylactic intervention, high doses of MS‐275 prevented bone erosion and markedly delayed the onset of arthritis; at low doses, MS‐275 strongly attenuated paw swelling, bone erosion, and bone resorption associated with RA. Furthermore, the therapeutic efficacy of MS‐275 was also documented. After the onset of arthritis, it could stop the disease progression and joint destruction. An anti inflammatory effect of MS‐275 was also confirmed through its capacity to decrease serum IL‐6 and IL‐1β levels in the CIA induced mouse model. The anti‐rheumatic activity of MS‐275 was also confirmed through histological observation. No synovial hyperplasia, pannus formation, cartilage or bone destruction were observed in the high dose prophylactic intervention in mice. Conclusion and implication: This study strongly supported HDACi as an innovative therapeutic strategy for RA. British Journal of Pharmacology (2007) 150, 862–872. doi:10.1038/sj.bjp.0707165
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolving concepts of rheumatoid arthritis
Firestein, G. S. (2003) · Nature · doi:10.1038/nature01661 · Cited by 3,605
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Lee, D. M., & Weinblatt, M. E. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06075-5 · Cited by 1,247
Guidelines for the management of rheumatoid arthritis: 2002 Update
American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines (2002) · Arthritis & Rheumatism · doi:10.1002/art.10148 · Cited by 1,185
Guidelines for the management of rheumatoid arthritis: 2002 Update
Yood, R. A. (2002) · Cited by 1,090
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
A microtomographic system for the nondestructive evaluation of bone architecture
Rüegsegger, P., Koller, B., & Müller, R. (1996) · Calcified Tissue International · doi:10.1007/bf02509542 · Cited by 893
Guidelines for the Management of Rheumatoid Arthritis 2002 Update
Goolsby, M. J., & Newsome, G. (2002) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2002.tb00072.x · Cited by 855
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Low-Dose Methotrexate: A Mainstay in the Treatment of Rheumatoid Arthritis
Cronstein, B. N. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.2.3 · Cited by 535
Leoni, F., Zaliani, A., Bertolini, G., Porro, G., Pagani, P., Pozzi, P., Donà, G., Fossati, G., Sozzani, S., Azam, T., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.052702999 · Cited by 508
Ryan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., et al. (2002) · Oncogene · doi:10.1038/sj.onc.1205108 · Cited by 400 · cited 2×
“…the upregulation of the cell-cycle inhibitor p21 (Waf/Cip1) (Chung et al., 2003; Nishida et al., 2004; Jungel et al., 2006); inhibit angiogenesis (Deroanne et al., 2002; Mie Lee et al., 2003; Kim et al., 2004; Michaelis et al., 2004; Qian et al., 2004); and decrease the expression of…”
BackgroundLeoni, F., Fossati, G., Lewis, E. C., Lee, J.-K., Porro, G., Pagani, P., Modena, D., Moras, M. L., Pozzi, P., Reznikov, L. L., et al. (2005) · Molecular Medicine · doi:10.2119/2006-00005.dinarello · Cited by 337
Chung, Y.-L., Lee, M.-Y., Wang, A.-J., & Yao, L.-F. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00235-1 · Cited by 253
Bush, K. A., Farmer, K. M., Walker, J. S., & Kirkham, B. W. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10173 · Cited by 252
Rheumatoid cachexia: metabolic abnormalities, mechanisms and interventions
Rall, L. C. (2004) · Rheumatology · doi:10.1093/rheumatology/keh321 · Cited by 244
Histone deacetylase inhibitors: new drugs for the treatment of inflammatory diseases?
Blanchard, F., & Chipoy, C. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(04)03309-4 · Cited by 239
Qian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P., & Pili, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0540 · Cited by 229
Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo
Michaelis, M., Michaelis, U. R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R. A., Hoffmann, K., Kotchetkov, R., Busse, R., Nau, H., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.520 · Cited by 227
Nishida, K., Komiyama, T., Miyazawa, S., Shen, Z., Furumatsu, T., Doi, H., Yoshida, A., Yamana, J., Yamamura, M., Ninomiya, Y., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20709 · Cited by 216
Young, D. A., Lakey, R. L., Pennington, C. J., Jones, D., Kevorkian, L., Edwards, D. R., Cawston, T. E., & Clark, I. M. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1702 · Cited by 193
Mishra, N., Brown, D. R., Olorenshaw, I. M., & Kammer, G. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051507098 · Cited by 178
A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical Trials
Piekarz, R., & Bates, S. (2004) · Current Pharmaceutical Design · doi:10.2174/1381612043383980 · Cited by 174
Mie Lee, Y., Kim, S.-H., Kim, H.-S., Jin Son, M., Nakajima, H., Jeong Kwon, H., & Kim, K.-W. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02787-0 · Cited by 165
Chemokines in joint disease: the key to inflammation?
Haringman, J. J., Ludikhuize, J., & Tak, P. P. (2004) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.020529 · Cited by 157
Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen‐induced arthritis
Sims, N. A., Green, J. R., Glatt, M., Schlicht, S., Martin, T. J., Gillespie, M. T., & Romas, E. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20382 · Cited by 128
Huang, N., Katz, J. P., Martin, D. R., & Wu, G. D. (1997) · Cytokine · doi:10.1006/cyto.1996.0132 · Cited by 125
Saidenberg-Kermanac'h, N., Corrado, A., Lemeiter, D., deVernejoul, M. C., Boissier, M. C., & Cohen-Solal, M. E. (2004) · Bone · doi:10.1016/j.bone.2004.07.004 · Cited by 117
Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis
Shelton, D. L., Zeller, J., Ho, W.-H., Pons, J., & Rosenthal, A. (2005) · Pain · doi:10.1016/j.pain.2005.03.039 · Cited by 109
Biological Agents for Rheumatoid Arthritis: Targeting Both Physical Function and Structural Damage
Klinkhoff, A. V. (2004) · Drugs · doi:10.2165/00003495-200464120-00001 · Cited by 98
Walsmith, J., Abad, L. W., Kehayias, J. J., et al. (2004) · PubMed · Cited by 90
Trichostatin A sensitises rheumatoid arthritis synovial fibroblasts for TRAIL-induced apoptosis
Jüngel, A., Barešová, V., Ospelt, C., Simmen, B. R., Michel, B. A., Gay, R. E., Gay, S., Seemayer, C. A., & Neidhart, M. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.044065 · Cited by 89
Apicidin is a histone deacetylase inhibitor with anti-invasive and anti-angiogenic potentials
Kim, S. H., Ahn, S.-H., Han, J., Lee, H. W., Lee, H. Y., Lee, Y., Kim, M. R., Kim, K. W., Kim, W. B., & Hong, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.01.149 · Cited by 77
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis
Bansback, N. J., Regier, D. A., Ara, R., Brennan, A., Shojania, K., Esdaile, J. M., Anis, A. H., & Marra, C. A. (2005) · Drugs · doi:10.2165/00003495-200565040-00004 · Cited by 73
Catabolic proinflammatory cytokines
Argilés, J. M. A., & López-Soriano, F. J. (1998) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-199805000-00002 · Cited by 71
Mukhopadhyay, N. K., Weisberg, E., Gilchrist, D., Bueno, R., Sugarbaker, D. J., & Jaklitsch, M. T. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2005.06.059 · Cited by 65
Thrombospondin 1 as an effective gene therapeutic strategy in collagen‐induced arthritis
Jou, I., Shiau, A., Chen, S., Wang, C., Shieh, D., Tsai, C., & Wu, C. (2005) · Arthritis & Rheumatism · doi:10.1002/art.20746 · Cited by 63
Infliximab treatment for rheumatic disease: clinical and radiological efficacy
Clair, E. W. S. (2002) · Annals of the Rheumatic Diseases · doi:10.1136/ard.61.suppl_2.ii67 · Cited by 42
Chung, Yl, Lee, My, Wang, Aj, & Yao (2006) · 中国生物学文摘 · Cited by 34
Jelaska (2000) · Pure Amsterdam UMC · doi:10.1002/1529-0131(200010)43:10 · Cited by 2
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Cited by
Epigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Duality of fibroblast-like synoviocytes in RA: passive responders and imprinted aggressors
Bottini, N., & Firestein, G. S. (2013) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.190 · Cited by 907
The pathogenesis of rheumatoid arthritis
Alivernini, S., Firestein, G. S., & McInnes, I. B. (2022) · Immunity · doi:10.1016/j.immuni.2022.11.009 · Cited by 702
Proteases involved in cartilage matrix degradation in osteoarthritis
Troeberg, L., & Nagase, H. (2012) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2011.06.020 · Cited by 579
Metadata
- Authors
- Lin, H., Hu, C., Chan, H., Liew, Y., Huang, H., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., & Clément‐Lacroix, P.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 2007-04
- Volume
- 150
- Issue
- 7
- Pages
- 862-872
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2028438001
- Cited by
- 272
- References
- 42
- FWCI
- 13.44
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.